KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Finished Goods: 2017-2020

Historic Finished Goods for Aquestive Therapeutics (AQST) over the last 4 years, with Dec 2020 value amounting to $544,000.

  • Aquestive Therapeutics' Finished Goods rose 42.80% to $1.0 million in Q1 2021 from the same period last year, while for Mar 2021 it was $1.0 million, marking a year-over-year increase of 42.80%. This contributed to the annual value of $544,000 for FY2020, which is 4.82% up from last year.
  • Per Aquestive Therapeutics' latest filing, its Finished Goods stood at $544,000 for FY2020, which was up 4.82% from $519,000 recorded in FY2019.
  • Aquestive Therapeutics' 5-year Finished Goods high stood at $1.2 million for FY2018, and its period low was $519,000 during FY2019.
  • Its 3-year average for Finished Goods is $748,667, with a median of $544,000 in 2020.
  • Per our database at Business Quant, Aquestive Therapeutics' Finished Goods grew by 11.18% in 2018 and then slumped by 56.13% in 2019.
  • Aquestive Therapeutics' Finished Goods (Yearly) stood at $1.1 million in 2017, then grew by 11.18% to $1.2 million in 2018, then slumped by 56.13% to $519,000 in 2019, then grew by 4.82% to $544,000 in 2020.